<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">568360</article-id><article-id pub-id-type="doi">10.26442/00403660.2023.06.202266</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Study of urinary markers of different podocytopathies by proteomic analysis</article-title><trans-title-group xml:lang="ru"><trans-title>Определение мочевых маркеров фокального сегментарного гломерулосклероза с помощью протеомного анализа</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7529-0215</contrib-id><name-alternatives><name xml:lang="en"><surname>Vinogradov</surname><given-names>Anatoliy A.</given-names></name><name xml:lang="ru"><surname>Виноградов</surname><given-names>Анатолий Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант каф. внутренних болезней фак-та фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова»</p></bio><email>anatoliy_vinogradov@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2128-8560</contrib-id><name-alternatives><name xml:lang="en"><surname>Chebotareva</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Чеботарева</surname><given-names>Наталья Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)</p></bio><email>anatoliy_vinogradov@list.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4568-7507</contrib-id><name-alternatives><name xml:lang="en"><surname>Bugrova</surname><given-names>Anna E.</given-names></name><name xml:lang="ru"><surname>Бугрова</surname><given-names>Анна Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. биол. наук, ст. науч. сотр. лаб. нейрохимии ФГБУН «ИБХФ им. Н.М. Эмануэля»</p></bio><email>anatoliy_vinogradov@list.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1128-1795</contrib-id><name-alternatives><name xml:lang="en"><surname>Brzhozovskiy</surname><given-names>Alexander G.</given-names></name><name xml:lang="ru"><surname>Бржозовский</surname><given-names>Александр Геннадьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. биол. наук, науч. сотр. лаб. масс-спектрометрии и омиксных технологий Центра наук о жизни АНОО ВО «Сколтех»</p></bio><email>anatoliy_vinogradov@list.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7647-3942</contrib-id><name-alternatives><name xml:lang="en"><surname>Krasnova</surname><given-names>Tatiana N.</given-names></name><name xml:lang="ru"><surname>Краснова</surname><given-names>Татьяна Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, зав. каф. внутренних болезней фак-та фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова», доц. каф. внутренних болезней ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)</p></bio><email>anatoliy_vinogradov@list.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nasibullina</surname><given-names>Karina Z.</given-names></name><name xml:lang="ru"><surname>Насибуллина</surname><given-names>Карина Зинуровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>студентка ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)</p></bio><email>anatoliy_vinogradov@list.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2238-3458</contrib-id><name-alternatives><name xml:lang="en"><surname>Kononikhin</surname><given-names>Alexey S.</given-names></name><name xml:lang="ru"><surname>Кононихин</surname><given-names>Алексей Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. физ.-мат. наук, ст. науч. сотр. лаб. масс-спектрометрии и омиксных технологий Центра наук о жизни АНОО ВО «Сколтех»</p></bio><email>anatoliy_vinogradov@list.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7232-4640</contrib-id><name-alternatives><name xml:lang="en"><surname>Moiseev</surname><given-names>Sergey V.</given-names></name><name xml:lang="ru"><surname>Моисеев</surname><given-names>Сергей Валентинович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>чл.-кор. РАН, д-р мед. наук, проф., зав. каф. внутренних, профессиональных болезней и ревматологии, дир. Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3 ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)</p></bio><email>anatoliy_vinogradov@list.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Emanuel Institute for Biochemical Physics</institution></aff><aff><institution xml:lang="ru">ФГБУН «Институт биохимической физики им. Н.М. Эмануэля» РАН</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Skolkovo Institute of Science and Technology</institution></aff><aff><institution xml:lang="ru">АНОО ВО «Сколковский институт науки и технологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-08-17" publication-format="electronic"><day>17</day><month>08</month><year>2023</year></pub-date><volume>95</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>457</fpage><lpage>461</lpage><history><date date-type="received" iso-8601-date="2023-08-14"><day>14</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-08-14"><day>14</day><month>08</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/568360">https://ter-arkhiv.ru/0040-3660/article/view/568360</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>Focal segmental glomerulosclerosis (FSGS) is a primary podocytopathy characterized by primary podocyte detection and high proteinuria. The search for biomarkers and factors associated with the progression of this disease is an important task nowdays.</p> <p><bold>Aim. </bold>To assess the proteomic profile of urine in patients with FSGS and to isolate urinary biomarkers of podocytopathies.</p> <p><bold>Materials and methods. </bold>The study included 41 patients diagnosed with chronic glomerulonephritis, 27 men and 14 women. According to the morphological study, 28 patients were diagnosed with FSGS, 9 with steroid-sensitive nephrotic syndrome and 14 with steroid-resistant nephrotic syndrome. The comparison group included 13 patients with membranous nephropathy. The study of the urinary proteome was carried out by targeted liquid chromatography-mass spectrometry using multiple reaction monitoring with synthetic stable isotope labelled peptide standards.</p> <p><bold>Results. </bold>The main differences in the protein profile of urine were found in the subgroups of steroid-sensitive (SS) and steroid-resistant (SR) FSGS. In the FSGS SR group, at the onset of the disease, there was a high concentration of proteins reflecting damage to the glomerular filter (apo-lipoprotein A-IV, orosomucoid, cadherin, hemopexin, vitronectin), as well as proteins associated with tubulo-interstitial inflammation and accumulation of extracellular matrix (retinol- and vitamin D-binding proteins, kininogen-1, lumican and neurophilin-2). Compared with the membranous nephropathy group, FSGS patients had significantly higher urinary concentrations of carnosinase, orosomucoid, cadherin-13, tenascin X, osteopontin, and zinc-alpha-2-glycoprotein.</p> <p><bold>Conclusion. </bold>Thus, in patients with SR FSGS, the proteomic profile of urine includes more proteins at elevated concentrations, which reflects severe damage to various parts of the nephron compared with patients with SS FSGS and membranous nephropathy.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Фокальный сегментарный гломерулосклероз (ФСГС) относится к первичным подоцитопатиям, которые характеризуются первичным повреждением подоцитов и высокой протеинурией. Поиск биомаркеров и факторов, участвующих в прогрессировании этого заболевания почек, является актуальной задачей в настоящее время.</p> <p><bold>Цель. </bold>Оценить протеомный профиль мочи у больных с ФСГС и выделить мочевые биомаркеры подоцитопатий.</p> <p><bold>Материалы и методы. </bold>В исследование включен 41 пациент с диагнозом хронического гломерулонефрита – 27 мужчин и 14 женщин. По данным морфологического исследования у 28 пациентов диагностирован ФСГС, у 9 – со стероид-чувствительным нефротическим синдромом и 14 – со стероид-резистентным (СР) нефротическим синдромом. В группу сравнения вошли 13 больных с мембранозной нефропатией. Исследование протеома мочи проводилось методом таргетной хромато-масс-спектрометрии в режиме мониторинга множественных реакций с использованием синтетических изотопно-меченых пептидных стандартов.</p> <p><bold>Результаты. </bold>Наибольшие различия по белковому составу мочи выявлены в подгруппах стероид-чувствительного и СР ФСГС. В группе СР ФСГС в дебюте заболевания отмечалось высокое содержание белков, отражающих повреждение гломерулярного фильтра (аполипопротеин А-IV, орозомукоид, кадгерин, гемопексин, витронектин), а также белков, связанных с тубуло-интерстициальным воспалением и накоплением экстрацеллюлярного матрикса (ретинол- и витамин-D-связывающие белки, кининоген-1, люмикан и нейрофилин-2). По сравнению с группой мембранозной нефропатии у больных с ФСГС отмечена достоверно более высокая концентрация в моче карнозиназы, орозомукоида, кадгерина-13, тенасцина X, остеопонтина, цинк-α-2-гликопротеина.</p> <p><bold>Заключение. </bold>Таким образом, у больных со СР ФСГС протеомный профиль мочи включает большее количество белков в повышенных концентрациях, что отражает тяжелое повреждение различных отделов нефрона по сравнению с больными со стероид-чувствительным ФСГС и мембранозной нефропатией.</p></trans-abstract><kwd-group xml:lang="en"><kwd>podocytopathies</kwd><kwd>focal segmental glomerulosclerosis</kwd><kwd>nephrotic syndrome</kwd><kwd>steroid-sensitive</kwd><kwd>steroid-resistant</kwd><kwd>urinary proteome</kwd><kwd>mass spectrometry</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>подоцитопатии</kwd><kwd>фокальный сегментарный гломерулосклероз</kwd><kwd>нефротический синдром</kwd><kwd>стероид-чувствительный</kwd><kwd>стероид-резистентный</kwd><kwd>протеом мочи</kwd><kwd>масс-спектрометрия</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The research was supported by a grant from the Russian Scientific Fund 21-74-20173.</funding-statement><funding-statement xml:lang="ru">Данное исследование поддержано грантом Российского научного фонда №21-74-20173.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Praga M, Morales E, Herrero JC, et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis. 1999;33(1):52-8. DOI:10.1016/s0272-6386(99)70257-x</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995;25(4):534-42. DOI:10.1016/0272-6386(95)90120-5</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sim JJ, Batech M, Hever A, et al. Distribution of biopsy-proven presumed primary glomerulonephropathies in 2000–2011 among a racially and ethnically diverse US population. Am J Kidney Dis. 2006;68:533-44. DOI:10.1053/j.ajkd.2016.03.416</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004;44(5):815-25. DOI:10.1053/j.ajkd.2004.07.008</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Coon JJ, Zürbig P, Dakna M, et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl. 2008;2:964-73. DOI:10.1002/prca.200800024</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kalantari S, Nafar M, Samavat S, et al. Urinary prognostic biomarkers in patients with focal segmental glomerulosclerosis. Nephrourol Mon. 2014;6(2):e16806. DOI:10.5812/numonthly.16806</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pérez V, López D, Boixadera E, et al. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis. BMC Nephrol. 2017;18(1):49. DOI:10.1186/s12882-017-0452-6</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Medyńska A, Chrzanowska J, Kościelska-Kasprzak K, et al. Alpha-1 Acid Glycoprotein and Podocin mRNA as Novel Biomarkers for Early Glomerular Injury in Obese Children. J Clin Med. 2021;10(18):4129. DOI:10.3390/jcm10184129</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Christiansen MS, Iversen K, Larsen CT, et al. Increased urinary orosomucoid excretion: A proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes. Scand J Clin Lab Investig. 2009;69:272-81. DOI:10.1080/00365510802531100</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kalantari S, Nafar M, Rutishauser D, et al. Predictive urinary biomarkers for steroid-resistant and steroid-sensitive focal segmental glomerulosclerosis using high resolution mass spectrometry and multivariate statistical analysis. BMC Nephrol. 2014;15:141. DOI:10.1186/1471-2369-15-141</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lingenhel A, Lhotta K, Neyer U, et al. Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria. J Lipid Res. 2006;47(9):2071-9. DOI:10.1194/jlr.M600178-JLR200</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kretzler M. Regulation of adhesive interaction between podocytes and glomerular basement membrane. Microsc Res Tech. 2002;57(4):247-53. DOI:10.1002/jemt.10083</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Yu CJ, Damaiyanti DW, Yan SJ, et al. The Pathophysiologic Role of Gelsolin in Chronic Kidney Disease: Focus on Podocytes. Int J Mol Sci. 2021;22(24):13281. DOI:10.3390/ ijms222413281</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kapojos JJ, Poelstra K, Borghuis T, et al. Regulation of plasma hemopexin activity by stimulated endothelial or mesangial cells. Nephron Physiol. 2004;96(1):1-10. DOI:10.1159/000075574</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Pukajło-Marczyk A, Zwolińska D. Involvement of Hemopexin in the Pathogenesis of Proteinuria in Children with Idiopathic Nephrotic Syndrome. J Clin Med. 2021;10(14):3160. DOI:10.3390/jcm10143160</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Lennon R, Singh A, Welsh GI, et al. Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol. 2008;19(11):2140-9. DOI:10.1681/ASN.2007080940</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Shen J, Zhu Y, Zhang S, et al. Vitronectin-activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells. Cell Prolif. 2021;54(4):e13012. DOI:10.1111/cpr.13012</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Choudhary A, Mohanraj PS, Krishnamurthy S, Rajappa M. Association of Urinary Vitamin D Binding Protein and Neutrophil Gelatinase-Associated Lipocalin with Steroid Responsiveness in Idiopathic Nephrotic Syndrome of Childhood. Saudi J Kidney Dis Transpl. 2020;31(5):946-56. DOI:10.4103/1319-2442.301201</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Mirković K, Doorenbos CR, Dam WA, et al. Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS One. 2013;8(2):e55887. DOI:10.1371/journal.pone.0055887</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Bennett MR, Pordal A, Haffner C, et al. Urinary Vitamin D-Binding Protein as a Biomarker of Steroid-Resistant Nephrotic Syndrome. Biomark Insights. 2016;11:1-6. DOI:10.4137/BMI.S31633</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Gonzalez-Calero L, Martin-Lorenzo M, Ramos-Barron A, et al. Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient prognosis? Sci Rep. 2016;6:19667. DOI:10.1038/srep19667</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mastroianni Kirsztajn G, Nishida SK, Silva MS, et al. Urinary retinol-binding protein as a prognostic marker in the treatment of nephrotic syndrome. Nephron. 2000;86(2):109-14. DOI:10.1159/000045727</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Krishnan A, Li X, Kao WY, Viker K, et al. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab Invest. 2012;92(12):1712-25. DOI:10.1038/labinvest.2012.121</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Schramek H, Sarközi R, Lauterberg C, et al. Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. Lab Invest. 2009;89(11):1304-16. DOI:10.1038/labinvest.2009.96</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Xie Q, Zhang M, Mao X, et al. Matrix protein Tenascin-C promotes kidney fibrosis via STAT3 activation in response to tubular injury. Cell Death Dis. 2022;13(12):1044. DOI:10.1038/s41419-022-05496-z</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Steinbrenner I, Sekula P, Kotsis F, el al. Association of osteopontin with kidney function and kidney failure in chronic kidney disease patients: the GCKD study. Nephrol Dial Transplant. 2022:gfac173. DOI:10.1093/ndt/gfac173</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Riedl E, Pfister F, Braunagel M, et al. Carnosine prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats. Cell Physiol Biochem. 2011;28(2):279-88. DOI:10.1159/000331740</mixed-citation></ref></ref-list></back></article>
